Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Shares Outstanding (Diluted Average) (2016 - 2025)

Capricor Therapeutics has reported Shares Outstanding (Diluted Average) over the past 9 years, most recently at $46.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 31.97% year-over-year to $46.5 million; the TTM value through Dec 2025 reached $46.5 million, up 31.97%, while the annual FY2025 figure was $46.5 million, 31.97% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $46.5 million at Capricor Therapeutics, up from $45.7 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $46.5 million in Q4 2025 and troughed at $22.2 million in Q1 2021.
  • A 5-year average of $30.3 million and a median of $25.4 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): soared 107.74% in 2021 and later rose 3.97% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $23.1 million in 2021, then grew by 6.34% to $24.6 million in 2022, then rose by 9.06% to $26.8 million in 2023, then soared by 31.52% to $35.2 million in 2024, then skyrocketed by 31.97% to $46.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CAPR at $46.5 million in Q4 2025, $45.7 million in Q3 2025, and $45.7 million in Q2 2025.